Small Molecules for Precision Medicine

Learn More about Arqule

We are pursuing multiple programs in biomarker-defined oncology and rare disease indications

Targeted Approach to Cancer

Clinical Trials

Learn More

Research & Development

Product Pipeline

Explore

Targeted Approach To

Rare Diseases

Read More

News & Events

September 29, 2017
Proteus Syndrome Phase 1 Data Presentation
Watch Video »
April 17, 2018
ArQule and Basilea Enter into Exclusive License Agreement for Derazantinib in the US, EU, Japan and Rest of World excluding Greater China
Read More »
May 7, 2018
ArQule Reports First Quarter 2018 Financial Results
Read More »

More News & Events »

arqule

© Copyright ArQule. All rights reserved. Terms of Use.